Elyse Rafal, MD
Dermatology · Stony Brook, NYNPI 1477515781
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,769 of the $20,426 with a category attached, or 87.0%. It is spread thinly across 41 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $7,236 and has fallen 56.9% since, to $3,117 in 2025.
Across 556 payments — averaging $36.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arcutis Biotherapeutics, Inc.$3K
- LEO Pharma Inc.$2K
- Pfizer$1K
- AbbVie$1K
- Janssen Scientific Affairs, LLC$1K
- Sun Pharmaceutical Industries Inc.$1K
- plus $10K from 35 others
Across 253 payments — averaging $5672.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$350K
- AbbVie$295K
- Janssen Research & Development, LLC$185K
- Takeda Pharmaceuticals U.S.A., Inc.$163K
- E.r. Squibb & Sons, L.L.C.$120K
- Pfizer$103K
- plus $220K from 10 others
What the payments were for
- Consulting fees$2,45012%
- Speaking & faculty fees$830%
- Travel & lodging$1101%
- Food & beverage$17,76987%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,426 in reported general payments places this provider in the 85th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Calcipotriene | 11 | $19,368 |
| Oxiconazole Nitrate | 11 | $7,228 |
| Ketoconazole | 95 | $1,471 |
| Tavaborole | 11 | $1,456 |
| Clindamycin Phosphate | 34 | $617 |
| Ciclopirox | 15 | $491 |
| Doxycycline Hyclate | 18 | $259 |
| Nystatin | 11 | $113 |
| Mupirocin | 20 | $103 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Stony Brook
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
- Emma GuttmanNew York$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.